Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection
| Autor: | Hélène Schuhmacher, Sibylle Bevilacqua, Thierry May, Philippe Canton, Christian Rabaud, Véronique Dorvaux, Isabelle Beguinot |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Anti-HIV Agents medicine.medical_treatment education HIV Infections Zidovudine Acquired immunodeficiency syndrome (AIDS) Internal medicine Medicine Humans Prospective Studies Post-exposure prophylaxis Adverse effect Nelfinavir business.industry virus diseases Lamivudine medicine.disease Virology Infectious Diseases Tolerability Chemoprophylaxis cardiovascular system Reverse Transcriptase Inhibitors Drug Therapy Combination business medicine.drug |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 32(10) |
| ISSN: | 1058-4838 |
| Popis: | Tolerability of the combination of zidovudine, lamivudine, and nelfinavir used as postexposure prophylaxis (PEP) for HIV infection was prospectively evaluated among 185 patients at 11 hospitals in eastern France. After exclusion of the 106 persons who discontinued PEP either because the source patient subsequently tested HIV seronegative or because the injury was reassessed as resulting in a low risk for transmission of HIV, 67 (85%) of the patients who received such PEP experienced adverse effects, which led to withdrawal of nelfinavir in 28 (35%) of these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|